We could not find any results for:
Make sure your spelling is correct or try broadening your search.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} ...
Press release 30 January 2019 First patients included in large placebo-controlled multicentre study on ColdZyme Enzymatica has initiated a prospective double-blind, placebo-controlled multicentre...
Press release 25 January 2019 Results from German multicentre study strengthen and broaden ColdZyme's product claims At the Icelandic Medical Association conference in Reykjavik on 24...
Press release December 10, 2018 Appeal on Enzymatica's cold spray in Germany overruled Enzymatica has been informed that the Frankfurt Higher Regional Court - OLG (Oberlandesgericht) has...
Press release December 2, 2018 NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR NEW ZEELAND...
Press release November 12, 2018 NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR NEW ZEELAND...
Press release5 November, 2018 Bulletin from Extraordinary General Meeting in Enzymatica AB (publ) Today's Extraordinary General Meeting in Enzymatica AB (publ) resolved to approve the Board...
Press release November 2, 2018 Enzymatica's rights issue is secured up to 100 percent Enzymatica announced on October 18, 2018 that the Board of Directors has decided to carry out a rights...
Interim report for Enzymatica AB (publ)JANUARY-SEPTEMBER 2018 ...
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Press releaseLund on October 18...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions